The primary objective of this study was to evaluate the pharmacokinetics (PK) of THC, 11-OH-THC and CBD following a single inhaled dose of PPP001 administered by vaporization. The secondary objective of this study was to determine the safety and tolerability of THC and CBD after a single inhaled dose of PPP001 administered by vaporization in healthy volunteers.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Assessment of adverse events [Safety and Tolerability]
Timeframe: over 5 days
Biochemistry test results [Safety and Tolerability]
Timeframe: over 5 days
Temperature [Safety and Tolerability]
Timeframe: over 5 days
Pulse rate [Safety and Tolerability]
Timeframe: over 5 days
Blood pressure [Safety and Tolerability]
Timeframe: over 5 days
Clinically significant ECG abnormalities [Safety and Tolerability]
Timeframe: over 5 days
Plasma concentrations of delta-9-tetrahydrocannabinol produced by PPP001 were determined. (pharmacokinetics)
Timeframe: over 5 days
Plasma concentrations of 11-OH-delta-9-tetrahydrocannabinol produced by PPP001 were determined. (pharmacokinetics)
Timeframe: over 5 days
Plasma concentrations of cannabidiol produced by PPP001 were determined. (pharmacokinetics)
Timeframe: over 5 days